1. A novel CXCR4 antagonist IgG1 antibody (PF-06747143) for the treatment of hematologic malignancies
- Author
-
Liu, Shu-Hui, Gu, Yin, Pascual, Bernadette, Yan, Zhengming, Hallin, Max, Zhang, Cathy, Fan, Conglin, Wang, Wenlian, Lam, Justine, Spilker, Mary E., Yafawi, Rolla, Blasi, Eileen, Simmons, Brett, Huser, Nanni, Ho, Wei-Hsien, Lindquist, Kevin, Tran, Thomas-Toan, Kudaravalli, Jyothirmayee, Ma, Jing-Tyan, Jimenez, Gretchen, Barman, Ishita, Brown, Colleen, Chin, Sherman Michael, Costa, Maria J., Shelton, David, Smeal, Tod, Fantin, Valeria R., and Pernasetti, Flavia
- Abstract
The chemokine receptor CXCR4 is highly expressed and associated with poor prognosis in multiple malignancies. Upon engagement by its ligand, CXCL12, CXCR4 triggers intracellular signaling pathways that control trafficking of cells to tissues where the ligand is expressed, such as the bone marrow (BM). In hematologic cancers, CXCR4-driven homing of malignant cells to the BM protective niche is a key mechanism driving disease and therapy resistance. We developed a humanized CXCR4 immunoglobulin G1 (IgG1) antibody (Ab), PF-06747143, which binds to CXCR4 and inhibits CXCL12-mediated signaling pathways, as well as cell migration. In in vivo preclinical studies, PF-06747143 monotherapy rapidly and transiently mobilized cells from the BM into the peripheral blood. In addition, PF-06747143 effectively induced tumor cell death via its Fc constant region–mediated effector function. This Fc-mediated cell killing mechanism not only enhanced antitumor efficacy, but also played a role in reducing the duration of cell mobilization, when compared with an IgG4 version of the Ab, which does not have Fc-effector function. PF-06747143 treatment showed strong antitumor effect in multiple hematologic tumor models including non-Hodgkin lymphoma (NHL), acute myeloid leukemia (AML), and multiple myeloma (MM). Importantly, PF-06747143 synergized with standard-of-care agents in a chemoresistant AML patient-derived xenograft model and in an MM model. These findings suggest that PF-06747143 is a potential best-in-class anti-CXCR4 antagonist for the treatment of hematologic malignancies, including in the resistant setting. PF-06747143 is currently in phase 1 clinical trial evaluation (registered at www.clinicaltrials.gov as #NCT02954653).
- Published
- 2017
- Full Text
- View/download PDF